Overview

Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma (ASPEN-03)

Status:
Recruiting
Trial end date:
2024-10-01
Target enrollment:
Participant gender:
Summary
A Phase 2 Study of Evorpacept (ALX148) in Combination With Pembrolizumab in Patients With Advanced Head and Neck Squamous Cell Carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
ALX Oncology Inc.
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Pembrolizumab